
GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led Phase II trial. The NERO study (NCT05455424) investigated the efficacy of Zejula in 88 mesothelioma patients who relapsed …